Institut für Medizininformatik, Biometrie und Epidemiologie

Formaldehyde 2% is not a useful means of detecting allergy to formaldehyde releasers— results of the ESSCA network, 2015-2018 (2020) Whitehouse H, Uter W, Geier J, Ballmer-Weber B, Bauer A, Cooper S, Czarnecka-Operacz M, et al. Journal article Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma – A Prospective Multicenter DEGUM Study (2020) Schellhaas B, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich CF, Dirks K, et al. Journal article R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial (2020) Fietkau R, Grützmann R, Wittel UA, Croner RS, Jacobasch L, Neumann UP, Reinacher-Schick A, et al. Journal article The effect of different test protocols and walking distances on gait speed in older persons (2020) Krumpoch S, Lindemann U, Rappl A, Becker C, Sieber C, Freiberger E Journal article Thrombin Generation in Fresh and Frozen-Thawed Platelet Poor Plasma - Is there a Difference? (2020) Kausche LE, Adler W, Zimmermann R, Hackstein H, Strasser E Journal article Use of CAD-based pre-bent implants reduces theatre time in orbital floor reconstruction: results of a prospective study (2020) von Wilmowsky C, Schwertner M, Nkenke E, Möst T, Adler W, Ebker T Journal article Measuring the cellular memory B cell response after vaccination in patients after allogeneic stem cell transplantation (2020) Winkler J, Tittlbach H, Schneider A, Buchstaller C, Mayr A, Vasova I, Rösler W, et al. Journal article Forecasting Based on Surveillance Data (2020) Held L, Meyer S Book chapter / Article in edited volumes European Task Force on Contact Dermatitis statement on coronavirus 19 disease (COVID-19) outbreak and the risk of adverse cutaneous reactions (2020) Balato A, Ayala F, Bruze M, Crepy MN, Gonçalo M, Duus Johansen J, John SM, et al. Journal article Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study (2020) Fischer S, Mesfin SE, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Conference contribution